Oculus Innovative Sciences, Inc.
1129 North Mcdowell Boulevard
Petaluma,
CA 94954
United States - Map
Phone: 707-782-0792
Fax: 707-283-0551
Web Site: http://www.oculusis.com
| Oculus Innovative Sciences, Inc., a biopharmaceutical company, together with its subsidiaries, develops, manufactures, and markets products based on Microcyn platform technology that intends to help prevent and treat infections in chronic and acute wounds. Its Microcyn platform technology, an oxychlorine small molecule formulation, treats various organisms that cause disease or pathogens, including viruses, fungi, and spores, as well as antibiotic resistant strains of bacteria, such as Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococcus in wounds. The company offers Microcyn-based products primarily through its website, and various regional distributors in the United States. It sells its products to hospitals, physicians, and nurses; and other healthcare practitioners who are the caregivers to patients being treated for acute or chronic wounds, as well as those patients undergoing surgical procedures. The company has a strategic partnership with V&M Industries Inc. for to market Microcyn-based skin and wound care over-the-counter products in the United States and Canada. The company was formerly known as Micromed Laboratories, Inc. and changed its name to Oculus Innovative Sciences, Inc. in August 2001. Oculus Innovative Sciences was incorporated in 1999 and is based in Petaluma, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Hojabr Alimi , 47
Co-Founder, Chairman, Chief Exec. Officer, Pres and Member of Acquisition & Strategy Committee |
N/A
| N/A | Mr. Robert E. Miller , 66
Chief Financial Officer and Principal Accounting Officer |
N/A
| N/A | Mr. Bruce Thornton , 45
Exec. VP |
N/A
| N/A | Mr. James Schutz , 46
VP of Corp. Devel., Corp. Sec., Gen. Counsel, Director and Member of Acquisition & Strategy Committee |
N/A
| N/A | Mr. Robert Northey Ph.D., 52
VP of R&D |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
0.04 (2.88%) 
Profile
